no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
1 |
Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia
|
Depies, Olivia M. |
|
|
2 |
1 |
p. |
article |
2 |
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
|
Pemmaraju, Naveen |
|
|
2 |
1 |
p. |
article |
3 |
A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies
|
Gordon, Max J. |
|
|
2 |
1 |
p. |
article |
4 |
Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells
|
Kang, Jongseok |
|
|
2 |
1 |
p. |
article |
5 |
Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol
|
Yeung, David T. |
|
|
2 |
1 |
p. |
article |
6 |
Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma
|
Tran, Son |
|
|
2 |
1 |
p. |
article |
7 |
JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study
|
Uemura, Yu |
|
|
2 |
1 |
p. |
article |
8 |
Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL
|
Cox, Willem P. J. |
|
|
2 |
1 |
p. |
article |
9 |
Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma
|
Jo, Tomoyasu |
|
|
2 |
1 |
p. |
article |
10 |
Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study
|
Trabolsi, Asaad |
|
|
2 |
1 |
p. |
article |
11 |
Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma
|
Wiedmeier-Nutor, Julia Erin |
|
|
2 |
1 |
p. |
article |
12 |
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma
|
Wang, Bei |
|
|
2 |
1 |
p. |
article |
13 |
Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial
|
Iyer, Swaminathan P. |
|
|
2 |
1 |
p. |
article |
14 |
Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States
|
Davids, Matthew S. |
|
|
2 |
1 |
p. |
article |
15 |
Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
|
Hafer, Ramsay |
|
|
2 |
1 |
p. |
article |
16 |
Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis
|
Fonseca, Rodrigo |
|
|
2 |
1 |
p. |
article |
17 |
Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma
|
Kobayashi, Hiroki |
|
|
2 |
1 |
p. |
article |